Literature DB >> 3120125

A review of the published data on steroids and idiopathic facial paralysis.

J A Stankiewicz1.   

Abstract

Ever since idiopathic facial paralysis (IFP) was first described, several treatments have been tried in an effort to influence early and full recovery. Unfortunately, none of these treatments was effective. After Rothendler's case description in 1951, a multitude of papers have appeared that evaluate the effectiveness of steroids in idiopathic facial paralysis. My presentation reflects a close evaluation of 94 of these papers. Only a few properly controlled, randomized, prospective studies were available. Their main conclusion was that steroid treatment was not more beneficial than conventional treatment. To the contrary, several other less valid prospective and retrospective studies suggest that steroid treatment is beneficial. The definitive, statistically valid study concerning the benefits of steroids in treatment of idiopathic facial paralysis has yet to be performed. Until then, treatment of idiopathic facial paralysis continues to be controversial.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120125     DOI: 10.1177/019459988709700509

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  4 in total

1.  Bell's Palsy and Herpes Zoster Oticus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

Review 2.  From evidence to action.

Authors:  Gary S Gronseth
Journal:  NeuroRx       Date:  2004-07

3.  The efficacy of intraoperative corticosteroids in recurrent laryngeal nerve palsy after thyroid surgery.

Authors:  Ling-Feng Wang; Ka-Wo Lee; Wen-Rei Kuo; Che-Wei Wu; Shang-Pin Lu; Feng-Yu Chiang
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

4.  The clinical problem of Bell's palsy: is treatment with steroids effective?

Authors:  I G Williamson; T R Whelan
Journal:  Br J Gen Pract       Date:  1996-12       Impact factor: 5.386

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.